What is the current Citalopram Hydrobromide Tablets market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Citalopram Hydrobromide Tablets market?

Increasing prevalence of depression and anxiety disorders are key drivers.

What are the major challenges facing the market?

Patent expirations and generic competition are significant challenges.

Which regions are leading the Citalopram Hydrobromide Tablets market?

North America and Europe are leading the market due to high demand.

Who are the top companies in the Citalopram Hydrobromide Tablets market?

Leading companies include Forest Laboratories and Teva Pharmaceutical Industries.

What future opportunities exist in the market?

Emerging markets and novel formulations offer future growth opportunities.

How is technology impacting the Citalopram Hydrobromide Tablets market?

Advances in drug delivery systems are improving treatment outcomes.

What is the current regulatory landscape for the market?

Regulatory bodies are enforcing strict quality control measures.

What is the future outlook for the Citalopram Hydrobromide Tablets market size?

The market is expected to reach USD 1.8 billion by 2033.

Citalopram Hydrobromide Tablets - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Citalopram Hydrobromide Tablets by Application (Hospital, Clinic, Other), by Types (12 Tablets/Box, 14 Tablets/Box), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Citalopram Hydrobromide Tablets Market Size | CAGR 4.2 Forecast 2033

Citalopram Hydrobromide Tablets - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Citalopram Hydrobromide Tablets Market Overview

The Citalopram Hydrobromide Tablets market is a significant sector within the pharmaceutical industry, playing a crucial role in the treatment of depression and anxiety disorders. As a key player in the antidepressant market, the Citalopram Hydrobromide Tablets market size is estimated to be around $1.3 billion. The growth outlook for this market is promising, with a market forecast indicating a steady increase in demand, driven by the rising prevalence of mental health disorders and the growing need for effective treatments, ultimately contributing to the industry expansion. The scope of this market encompasses the development, manufacturing, and distribution of Citalopram Hydrobromide Tablets, including generic and branded versions, across various geographies and therapeutic applications.

Loading chart…

The Citalopram Hydrobromide Tablets market is expected to grow at a CAGR of around 4-5% during the forecast period, driven by macro drivers such as the increasing awareness of mental health, advancements in pharmaceutical technology, and the rising demand for generic medications. Key forces shaping the industry include regulatory reforms, competitive intensity, and supply-chain dynamics. The largest region for this market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the growing healthcare infrastructure and the increasing prevalence of mental health disorders. Overall, the Citalopram Hydrobromide Tablets market is poised for steady growth, driven by the rising demand for effective treatments and the expanding therapeutic applications of these medications.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	625.39 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Kelun Pharmaceutical; Enhua Pharmaceutical; Yinuo Medicine; SHODHANA; Cipla Inc.; Mahban Group; Virupaksha; Index Pharmaceutical; Northeast Pharmaceutical Group; China Resources Sanjiu Pharmaceutical; Hanhui Pharmaceutical; Southwest Pharmaceutical; H. Lundbeck
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Citalopram Hydrobromide Tablets market is witnessing significant transformations, driven by various factors that are shaping its growth trajectory. This section delves into the key dynamics influencing the market, including growth drivers, restraints, opportunities, and challenges.

Growth Drivers2 items

Increasing prevalence of depression and anxiety disorders is fueling the demand for Citalopram Hydrobromide Tablets, thereby driving the market size and growth forecast.

Advancements in pharmaceutical technology and manufacturing processes are enabling the production of high-quality Citalopram Hydrobromide Tablets, which is further augmenting market growth.

Restraints2 items

Stringent regulatory requirements and intense competition in the Citalopram Hydrobromide Tablets market are posing challenges for new entrants, thereby hindering market growth.

Side effects associated with Citalopram Hydrobromide Tablets, such as withdrawal symptoms and allergic reactions, are limiting their adoption and affecting the overall market size.

Opportunities2 items

Growing demand for generic and affordable Citalopram Hydrobromide Tablets in emerging economies presents a significant opportunity for manufacturers to expand their market share and increase the Citalopram Hydrobromide Tablets market size.

Increasing investments in research and development are expected to lead to the discovery of new indications for Citalopram Hydrobromide Tablets, further driving market growth and growth forecast.

Challenges2 items

Fluctuations in raw material prices and supply chain disruptions are affecting the production costs and availability of Citalopram Hydrobromide Tablets, thereby impacting the market dynamics.

Intense competition and pricing pressure in the Citalopram Hydrobromide Tablets market are forcing manufacturers to adopt strategies that balance profitability with affordability, making it a significant challenge for market players.

Market Segmentation

Loading chart…

The Application segment of the Citalopram Hydrobromide Tablets market refers to the various uses of these tablets in treating different medical conditions. This segment is crucial in understanding the Citalopram Hydrobromide Tablets segmentation as it directly impacts the market size. The application segment includes treatment of depression, anxiety disorders, and other mental health conditions, contributing to the overall market size.

The Types segment of the Citalopram Hydrobromide Tablets market includes subtypes such as immediate-release and extended-release tablets. This segment is vital in market taxonomy as it helps in identifying the specific product types that are in high demand. The types segment contributes to the overall market size by providing a detailed understanding of the product offerings in the Citalopram Hydrobromide Tablets market.

Citalopram Hydrobromide Tablets Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

12 Tablets/Box

14 Tablets/Box

Regional Insights

Loading chart…

The Citalopram Hydrobromide Tablets market growth is expected to vary across regions, with the largest share held by North America, accounting for approximately 35% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of citalopram hydrobromide tablets in countries such as China and India.

Key drivers for the North America region include high adoption rates, favorable policies, and significant investments in mental health infrastructure. In Europe, drivers include established healthcare infrastructure, growing awareness of mental health issues, and mature ecosystem for pharmaceuticals. Asia Pacific's growth is driven by increasing demographics, expanding infrastructure, and rising investments in healthcare.

Latin America's regional forecast is influenced by growing demand for citalopram hydrobromide tablets, improving infrastructure, and increasing adoption in countries such as Brazil. The Middle East & Africa region is driven by government initiatives, rising awareness of mental health, and investments in healthcare infrastructure.

Competitive Landscape

The Citalopram Hydrobromide Tablets market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, and product innovation. The Citalopram Hydrobromide Tablets competitive landscape is driven by key competitive levers, including regulatory approvals and certifications. Global players are focusing on expanding their product portfolio, while local companies are emphasizing regional distribution networks.

Companies in the market are adopting various strategies to differentiate themselves, including partnerships, product launches, and expansion into new regions. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies are focusing on technology, service model, and channel strength to differentiate themselves. Some companies are also emphasizing cost advantages and customization to attract price-sensitive customers.

Kelun Pharmaceutical: regional expansion

Enhua Pharmaceutical: vertical integration

Yinuo Medicine: premium pricing

SHODHANA: OEM tie-ups

Cipla Inc.: innovation pipeline

Mahban Group: local manufacturing

Key Citalopram Hydrobromide Tablets Companies13 items

Kelun Pharmaceutical

Enhua Pharmaceutical

Yinuo Medicine

SHODHANA

Cipla Inc.

Mahban Group

Virupaksha

Index Pharmaceutical

Northeast Pharmaceutical Group

China Resources Sanjiu Pharmaceutical

Hanhui Pharmaceutical

Southwest Pharmaceutical

H. Lundbeck

Market Ecosystem

The Citalopram Hydrobromide Tablets ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of Citalopram Hydrobromide Tablets, with various participants contributing to the ecosystem's overall efficiency and effectiveness.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing Citalopram Hydrobromide Tablets

Distributors/channel partners — delivering products to end users

End users/buyers — consuming Citalopram Hydrobromide Tablets

Regulators/standards bodies — overseeing safety and efficacy standards

Service providers/after-sales — offering support and maintenance services

Data/analytics providers — supplying market insights and research

In the Citalopram Hydrobromide Tablets ecosystem, value flows through the interactions and dependencies among participants. Control points, such as regulatory approvals and distribution channels, influence adoption and market penetration. Dependency risks, including input constraints and standards compliance, can impact the ecosystem's efficiency. Furthermore, switching costs, partnerships, and interoperability requirements can affect the dynamics of the ecosystem, which may differ by region due to varying regulatory frameworks and market conditions, highlighting the need for a thorough value chain analysis to navigate the complex Citalopram Hydrobromide Tablets ecosystem.

Recent Industry Insights

The Citalopram Hydrobromide Tablets industry trends have witnessed significant developments in the last 12-18 months. Notably, there have been key partnerships between pharmaceutical companies to enhance production capacities and expand their market presence. Additionally, several mergers and acquisitions have taken place, leading to consolidation in the industry. Recent product launches have also focused on improving the efficacy and safety of Citalopram Hydrobromide Tablets, aligning with the growing demand for high-quality medications. Furthermore, regulatory changes have emphasized the need for stricter quality control measures, prompting companies to invest in research and development.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Citalopram Hydrobromide Tablets market. The market attractiveness of Citalopram Hydrobromide Tablets is moderate, driven by increasing demand for antidepressants. The competitive intensity is high, with multiple players operating in the market. The long-term outlook for the Citalopram Hydrobromide Tablets market outlook is positive, with growing awareness about mental health driving demand.

The innovation landscape is evolving, with companies focusing on developing new formulations and delivery systems. The demand–supply balance is currently stable, but may shift due to changes in regulatory policies. Key risk factors include intense competition, patent expirations, and regulatory challenges. Overall, the Citalopram Hydrobromide Tablets market is expected to grow, driven by increasing demand and advancements in treatment options.

12 items

1. Executive Summary

2. Citalopram Hydrobromide Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Citalopram Hydrobromide Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Citalopram Hydrobromide Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Citalopram Hydrobromide Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Citalopram Hydrobromide Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Citalopram Hydrobromide Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Citalopram Hydrobromide Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Citalopram Hydrobromide Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Citalopram Hydrobromide Tablets Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Citalopram Hydrobromide Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Citalopram Hydrobromide Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Citalopram Hydrobromide Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Citalopram Hydrobromide Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Citalopram Hydrobromide Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Citalopram Hydrobromide Tablets Market Competition by Key Manufacturers

9.1. Global Citalopram Hydrobromide Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Citalopram Hydrobromide Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Kelun Pharmaceutical

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Enhua Pharmaceutical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Yinuo Medicine

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. SHODHANA

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cipla Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Mahban Group

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Virupaksha

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Index Pharmaceutical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Northeast Pharmaceutical Group

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. China Resources Sanjiu Pharmaceutical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Hanhui Pharmaceutical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Southwest Pharmaceutical

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. H. Lundbeck

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Citalopram Hydrobromide Tablets Market

Figure 4: Global Citalopram Hydrobromide Tablets Market: Drivers

Figure 5: Global Citalopram Hydrobromide Tablets Market: Challenges

Figure 6: Global Citalopram Hydrobromide Tablets Market: Trends

Figure 7: Global Citalopram Hydrobromide Tablets Market: Opportunity

Figure 8: Global Citalopram Hydrobromide Tablets Market: Restraint

Figure 9: Global Citalopram Hydrobromide Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Citalopram Hydrobromide Tablets Market Value (USD Million) By Region

Figure 19: Global Citalopram Hydrobromide Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Citalopram Hydrobromide Tablets Market Value (USD Million) By Region

Figure 27: Global Citalopram Hydrobromide Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Citalopram Hydrobromide Tablets Market Volume (K) By Region

Figure 29: Global Citalopram Hydrobromide Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Citalopram Hydrobromide Tablets Market Value (USD Million) By Region

Figure 37: Global Citalopram Hydrobromide Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Citalopram Hydrobromide Tablets Market Volume (K) By Region

Figure 39: Global Citalopram Hydrobromide Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Citalopram Hydrobromide Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Citalopram Hydrobromide Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Citalopram Hydrobromide Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Citalopram Hydrobromide Tablets Market Value (USD Million) By Region

Table 14: Global Citalopram Hydrobromide Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Citalopram Hydrobromide Tablets Market Volume (K) By Region

Table 31: Global Citalopram Hydrobromide Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Citalopram Hydrobromide Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Citalopram Hydrobromide Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Citalopram Hydrobromide Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Kelun Pharmaceutical Basic Information And Sales Area

Table 52: Kelun Pharmaceutical. Products Portfolio

Table 53: Enhua Pharmaceutical Basic Information And Sales Area

Table 54: Enhua Pharmaceutical. Products Portfolio

Table 55: Yinuo Medicine Basic Information And Sales Area

Table 56: Yinuo Medicine. Products Portfolio

Table 57: SHODHANA Basic Information And Sales Area

Table 58: SHODHANA. Products Portfolio

Table 59: Cipla Inc. Basic Information And Sales Area

Table 60: Cipla Inc.. Products Portfolio

Table 61: Mahban Group Basic Information And Sales Area

Table 62: Mahban Group. Products Portfolio

Table 63: Virupaksha Basic Information And Sales Area

Table 64: Virupaksha. Products Portfolio

Table 65: Index Pharmaceutical Basic Information And Sales Area

Table 66: Index Pharmaceutical. Products Portfolio

Table 67: Northeast Pharmaceutical Group Basic Information And Sales Area

Table 68: Northeast Pharmaceutical Group. Products Portfolio

Table 69: China Resources Sanjiu Pharmaceutical Basic Information And Sales Area

Table 70: China Resources Sanjiu Pharmaceutical. Products Portfolio

Table 71: Hanhui Pharmaceutical Basic Information And Sales Area

Table 72: Hanhui Pharmaceutical. Products Portfolio

Table 73: Southwest Pharmaceutical Basic Information And Sales Area

Table 74: Southwest Pharmaceutical. Products Portfolio

Table 75: H. Lundbeck Basic Information And Sales Area

Table 76: H. Lundbeck. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Citalopram Hydrobromide Tablets Market Value (USD Million) By Region

Table 86: Global Citalopram Hydrobromide Tablets Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Citalopram Hydrobromide Tablets Market Volume (K) By Region

Table 103: Global Citalopram Hydrobromide Tablets Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Citalopram Hydrobromide Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	625.39 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Kelun Pharmaceutical; Enhua Pharmaceutical; Yinuo Medicine; SHODHANA; Cipla Inc.; Mahban Group; Virupaksha; Index Pharmaceutical; Northeast Pharmaceutical Group; China Resources Sanjiu Pharmaceutical; Hanhui Pharmaceutical; Southwest Pharmaceutical; H. Lundbeck
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options